- Home
- OCUL vs IBRX Comparison
OCUL vs IBRX Comparison
Compare OCUL & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCUL
- IBRX
- Stock Information
- Founded
- OCUL 2006
- IBRX 2014
- Country
- OCUL United States
- IBRX United States
- Employees
- OCUL N/A
- IBRX N/A
- Industry
- OCUL Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OCUL Health Care
- IBRX Health Care
- Exchange
- OCUL Nasdaq
- IBRX Nasdaq
- Market Cap
- OCUL 2.3B
- IBRX 2.3B
- IPO Year
- OCUL 2014
- IBRX N/A
- Fundamental
- Price
- OCUL $11.26
- IBRX $2.53
- Analyst Decision
- OCUL Strong Buy
- IBRX Strong Buy
- Analyst Count
- OCUL 9
- IBRX 6
- Target Price
- OCUL $22.13
- IBRX $9.83
- AVG Volume (30 Days)
- OCUL 3.2M
- IBRX 10.3M
- Earning Date
- OCUL 11-13-2025
- IBRX 11-11-2025
- Dividend Yield
- OCUL N/A
- IBRX N/A
- EPS Growth
- OCUL N/A
- IBRX N/A
- EPS
- OCUL N/A
- IBRX N/A
- Revenue
- OCUL $56,664,000.00
- IBRX $56,600,000.00
- Revenue This Year
- OCUL N/A
- IBRX $629.94
- Revenue Next Year
- OCUL $18.87
- IBRX $109.91
- P/E Ratio
- OCUL N/A
- IBRX N/A
- Revenue Growth
- OCUL N/A
- IBRX 4227.22
- 52 Week Low
- OCUL $5.79
- IBRX $1.83
- 52 Week High
- OCUL $13.85
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- OCUL 41.98
- IBRX 47.77
- Support Level
- OCUL $10.85
- IBRX $2.42
- Resistance Level
- OCUL $11.77
- IBRX $2.75
- Average True Range (ATR)
- OCUL 0.72
- IBRX 0.13
- MACD
- OCUL -0.16
- IBRX -0.01
- Stochastic Oscillator
- OCUL 28.63
- IBRX 22.88
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.